PEGylated immunoliposomes co-delivering the P5 tumor peptide antigen and LAG3-Ig immune adjuvant induced superior dendritic cell maturation, T cell infiltration, tumor regression, and survival in a HER2+ breast cancer mouse model compared to free components.
Superior to soluble immunotherapyLiposome-based delivery of the P5 peptide + LAG3-Ig outperformed the same components in free solution across all immune and anti-tumor endpoints, demonstrating the critical role of multivalent presentation in vaccine efficacy.
What the researchers found
LAG3-Ig-P5-immunoliposomes outperformed soluble LAG3-Ig + P5 across all measured outcomes:
- Dendritic cell maturation: markedly induced by liposome-conjugated LAG3-Ig through multivalent MHC class II binding, more efficiently than free LAG3-Ig
- T cell responses: higher percentages of both CD4+ and CD8+ T cells in the spleen
- Tumor infiltration: more rapid and pronounced infiltration of effector T cells into tumor tissue
- Anti-tumor efficacy: greater tumor regression and prolonged survival in treated mice
The PEGylated liposome format enhanced LAG3-Ig's adjuvant activity by presenting it in a multivalent configuration that amplified its interaction with immune cells.
Why it matters
HER2-positive breast cancer affects about 20% of breast cancer patients and, despite existing therapies like trastuzumab, remains challenging to treat in advanced stages. Peptide-based cancer vaccines have shown promise but often generate weak immune responses on their own. This study demonstrates that presenting peptide antigens and immune adjuvants on liposomes dramatically improves vaccine efficacy — an approach that could be applied to other cancer peptide vaccines and potentially combined with existing HER2-targeted therapies.
The numbers in context
LAG3-Ig + P5 on PEGylated liposomes; enhanced DC maturation; higher CD4+/CD8+ infiltration; greater tumor regression + survival
How the study worked
Researchers prepared PEGylated liposomes with surface-conjugated LAG3-Ig (immune adjuvant) and P5 peptide (HER2/neu-derived tumor antigen). The immunoliposomes were characterized and tested in BALB/c mice bearing TUBO HER2/neu-positive breast tumors. Outcomes included dendritic cell maturation markers, splenic CD4+ and CD8+ T cell percentages, T cell infiltration into tumors, tumor growth measurement, and survival. Results were compared against soluble (non-liposomal) LAG3-Ig + P5 immunotherapy.
Who was studied
BALB/c mice with TUBO HER2/neu+ breast tumors
What this study cannot tell us
The study was conducted in a single mouse tumor model (TUBO/HER2+) using BALB/c mice, which may not represent the heterogeneity of human breast cancers. Manufacturing complexity of immunoliposomes with dual surface-conjugated proteins presents scalability challenges. The P5 peptide represents only one epitope of HER2, and immune escape through antigen loss is possible. Long-term immune memory and resistance to tumor rechallenge were not fully characterized. The study did not compare against existing HER2-targeted therapies like trastuzumab.
How to read the evidence
This is a preclinical animal study using a well-established breast cancer mouse model. The comprehensive assessment of immune responses and anti-tumor outcomes is a strength, but all findings are in mice and require human validation. The study represents proof-of-concept for the immunoliposome platform.
When this study was published
Published in 2021, this study is about 5 years old. Liposome-based cancer vaccines and LAG3-targeting immunotherapy continue to advance, with several LAG3 checkpoint inhibitors now in clinical trials or approved.
The bigger picture
This study illustrates the broader principle that how you deliver a vaccine matters as much as what's in it. Liposome-based delivery of peptide antigens and immune adjuvants is a growing strategy in cancer immunotherapy, offering advantages in antigen presentation, immune cell activation, and protection of fragile peptide components from degradation. The LAG3-based adjuvant approach is particularly interesting because LAG3 (lymphocyte activation gene 3) is also a target for checkpoint immunotherapy drugs, suggesting potential synergies between vaccination and checkpoint blockade strategies.
Questions still open
- Could LAG3-Ig-P5-immunoliposomes be combined with anti-HER2 antibodies (trastuzumab) or checkpoint inhibitors for enhanced anti-tumor effects?
- Would incorporating multiple HER2 peptide epitopes on the liposome surface reduce the risk of immune escape?
- Can this liposome-based vaccine platform be manufactured at clinical grade and scale for human trials?
Common questions
What are immunoliposomes and how do they work as a cancer vaccine?
Could this become a vaccine for breast cancer patients?
Read the original research
Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer.
Biotechnology progress, 37(2), e3095
Citation
Mohammadian Haftcheshmeh, Saeed; Zamani, Parvin; Mashreghi, Mohammad; Nikpoor, Amin Reza; Tavakkol-Afshari, Jalil; Jaafari, Mahmoud Reza. (2021). Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer.. Biotechnology progress, 37(2), e3095. https://doi.org/10.1002/btpr.3095